- Home
- EWTX vs CMRE Comparison
EWTX vs CMRE Comparison
Compare EWTX & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- CMRE
- Stock Information
- Founded
- EWTX 2017
- CMRE 1974
- Country
- EWTX United States
- CMRE Monaco
- Employees
- EWTX N/A
- CMRE N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- CMRE Marine Transportation
- Sector
- EWTX Health Care
- CMRE Consumer Discretionary
- Exchange
- EWTX Nasdaq
- CMRE Nasdaq
- Market Cap
- EWTX 1.2B
- CMRE 1.0B
- IPO Year
- EWTX 2021
- CMRE 2010
- Fundamental
- Price
- EWTX $14.70
- CMRE $7.79
- Analyst Decision
- EWTX Buy
- CMRE Hold
- Analyst Count
- EWTX 8
- CMRE 2
- Target Price
- EWTX $40.13
- CMRE $13.50
- AVG Volume (30 Days)
- EWTX 1.2M
- CMRE 530.4K
- Earning Date
- EWTX 05-08-2025
- CMRE 05-08-2025
- Dividend Yield
- EWTX N/A
- CMRE 5.91%
- EPS Growth
- EWTX N/A
- CMRE N/A
- EPS
- EWTX N/A
- CMRE 2.44
- Revenue
- EWTX N/A
- CMRE $2,054,690,000.00
- Revenue This Year
- EWTX N/A
- CMRE N/A
- Revenue Next Year
- EWTX N/A
- CMRE N/A
- P/E Ratio
- EWTX N/A
- CMRE $2.89
- Revenue Growth
- EWTX N/A
- CMRE 18.22
- 52 Week Low
- EWTX $10.60
- CMRE $6.63
- 52 Week High
- EWTX $38.12
- CMRE $17.58
- Technical
- Relative Strength Index (RSI)
- EWTX 42.22
- CMRE 36.14
- Support Level
- EWTX $14.08
- CMRE $6.63
- Resistance Level
- EWTX $17.30
- CMRE $9.68
- Average True Range (ATR)
- EWTX 1.00
- CMRE 0.29
- MACD
- EWTX 0.39
- CMRE -0.10
- Stochastic Oscillator
- EWTX 37.50
- CMRE 37.87
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.